Drug Approval | February 23, 2023
Moderna and Merck announce investigational personalized cancer vaccine mRNA-4157/V940
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
The new sterile filling line meets cGMP aseptic filling regulatory requirements
There is a fast resurgence in the transplant activities post COVID
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
Themis will market this drug with the brand name REMITHEM.
The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes
This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization
Subscribe To Our Newsletter & Stay Updated
